Literature DB >> 8049680

In vitro activity of mitochondrial ATP synthetase inhibitors against Plasmodium falciparum.

L K Basco1, J Le Bras.   

Abstract

The mitochondrion appears to be essential for the growth of asexual, intraerythrocytic stages of Plasmodium falciparum and may thus be a suitable chemotherapeutic target. The in vitro activity of almitrine, a mitochondrial ATP synthetase inhibitor used for the treatment of hypoxemia, was compared with other mitochondrial inhibitors against chloroquine-susceptible and chloroquine-resistant P. falciparum using an isotopic semimicro drug susceptibility assay. The 50% inhibitory concentration (IC50) values of almitrine (range: 2.6-19.8 microM) were within similar range of values of other mitochondrial ATP synthetase inhibitors and doxycycline, a mitochondrial protein synthesis inhibitor. Almitrine was equally active against chloroquine-susceptible and chloroquine-resistant parasites. Drug combination studies showed no interaction between chloroquine and almitrine. Our results suggest that almitrine, a clinically safe drug, may represent a lead compound with a specific target against the mitochondrial ATP synthetase which may be useful for antimalarial chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8049680     DOI: 10.1111/j.1550-7408.1994.tb01493.x

Source DB:  PubMed          Journal:  J Eukaryot Microbiol        ISSN: 1066-5234            Impact factor:   3.346


  2 in total

1.  Antimalarial dyes revisited: xanthenes, azines, oxazines, and thiazines.

Authors:  J L Vennerstrom; M T Makler; C K Angerhofer; J A Williams
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

2.  Drug Repurposing Based on Protozoan Proteome: In Vitro Evaluation of In Silico Screened Compounds against Toxoplasma gondii.

Authors:  Débora Chaves Cajazeiro; Paula Pereira Marques Toledo; Natália Ferreira de Sousa; Marcus Tullius Scotti; Juliana Quero Reimão
Journal:  Pharmaceutics       Date:  2022-08-05       Impact factor: 6.525

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.